CN107207431B - Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途 - Google Patents

Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途 Download PDF

Info

Publication number
CN107207431B
CN107207431B CN201680005731.2A CN201680005731A CN107207431B CN 107207431 B CN107207431 B CN 107207431B CN 201680005731 A CN201680005731 A CN 201680005731A CN 107207431 B CN107207431 B CN 107207431B
Authority
CN
China
Prior art keywords
compound
disease
cancer
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680005731.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107207431A (zh
Inventor
米尔顿·L·格林伯格
约翰·T·兰塞姆
克莱顿·A·怀特
欧米德·S·穆扎费里
安德鲁·C·纽曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivreon Biosciences LLC
Original Assignee
Vivreon Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivreon Biosciences LLC filed Critical Vivreon Biosciences LLC
Publication of CN107207431A publication Critical patent/CN107207431A/zh
Application granted granted Critical
Publication of CN107207431B publication Critical patent/CN107207431B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680005731.2A 2015-01-13 2016-01-11 Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途 Active CN107207431B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103033P 2015-01-13 2015-01-13
US62/103,033 2015-01-13
PCT/US2016/012909 WO2016115054A2 (en) 2015-01-13 2016-01-11 Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof

Publications (2)

Publication Number Publication Date
CN107207431A CN107207431A (zh) 2017-09-26
CN107207431B true CN107207431B (zh) 2021-02-09

Family

ID=56406559

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680005731.2A Active CN107207431B (zh) 2015-01-13 2016-01-11 Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途

Country Status (9)

Country Link
US (1) US10213412B2 (enExample)
EP (1) EP3245189B1 (enExample)
JP (1) JP6764866B2 (enExample)
CN (1) CN107207431B (enExample)
AU (1) AU2016207014B2 (enExample)
CA (1) CA2969814C (enExample)
ES (1) ES2825798T3 (enExample)
MX (1) MX379440B (enExample)
WO (1) WO2016115054A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2969814C (en) 2015-01-13 2023-06-13 Vivreon Biosciences, Llc Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof
BR112020007586A2 (pt) * 2017-10-17 2020-09-24 Rhizen Pharmaceuticals Sa moduladores de canal de crac para tratar câncer esofágico
KR20200079256A (ko) * 2017-10-30 2020-07-02 리젠 파마슈티컬스 소시에떼 아노님 혈액암 및 고형암을 치료하기 위한 칼슘 방출-활성화된 칼슘 채널 조절제
JP2022508468A (ja) 2018-09-14 2022-01-19 ルヒゼン ファーマスティカルズ アクツィエンゲゼルシャフト Ｃｒａｃ阻害剤およびコルチコステロイドを含む組成物ならびにそれらの使用方法
PH12022552447A1 (en) * 2020-03-16 2024-01-03 Zomagen Biosciences Ltd Nlrp3 modulators
AU2021273811A1 (en) * 2020-05-20 2022-12-22 Calcimedica, Inc. Methods and compositions for treating acute kidney injury

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4644009A (en) * 1984-10-29 1987-02-17 Usv Pharmaceutical Corporation Aryl-alkyl heterocyclic compounds
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
WO1993017671A1 (en) * 1992-03-06 1993-09-16 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites, or bacteria
WO1995019980A1 (en) * 1994-01-19 1995-07-27 Sankyo Company, Limited Pyrrolopyridazine derivative
CN101083985A (zh) * 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
CN102834382A (zh) * 2009-10-08 2012-12-19 理森制药股份公司 作为钙释放激活钙通道调节剂的吡唑衍生物
CN102958925A (zh) * 2009-10-08 2013-03-06 理森制药股份公司 吡唑衍生物钙释放激活钙通道调节剂及非小细胞肺癌的治疗方法
CN103781759A (zh) * 2011-06-27 2014-05-07 纽朗制药有限公司 氟化的芳基烷基氨基甲酰胺衍生物
WO2014203150A1 (en) * 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3143571B2 (ja) * 1994-01-19 2001-03-07 三共株式会社 ピロロピリダジン誘導体
JP2000256358A (ja) * 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
RU2008101805A (ru) * 2005-06-24 2009-07-27 Актелион Фармасьютиклз Лтд (Ch) Новые производные тиофена
TW201130488A (en) * 2010-02-03 2011-09-16 Daiichi Sankyo Co Ltd Pyrrole compound
CA2969814C (en) 2015-01-13 2023-06-13 Vivreon Biosciences, Llc Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4644009A (en) * 1984-10-29 1987-02-17 Usv Pharmaceutical Corporation Aryl-alkyl heterocyclic compounds
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
WO1993017671A1 (en) * 1992-03-06 1993-09-16 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites, or bacteria
WO1995019980A1 (en) * 1994-01-19 1995-07-27 Sankyo Company, Limited Pyrrolopyridazine derivative
CN101083985A (zh) * 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
CN102834382A (zh) * 2009-10-08 2012-12-19 理森制药股份公司 作为钙释放激活钙通道调节剂的吡唑衍生物
CN102958925A (zh) * 2009-10-08 2013-03-06 理森制药股份公司 吡唑衍生物钙释放激活钙通道调节剂及非小细胞肺癌的治疗方法
CN103781759A (zh) * 2011-06-27 2014-05-07 纽朗制药有限公司 氟化的芳基烷基氨基甲酰胺衍生物
WO2014203150A1 (en) * 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators

Also Published As

Publication number Publication date
EP3245189A4 (en) 2018-07-18
US10213412B2 (en) 2019-02-26
CA2969814C (en) 2023-06-13
MX379440B (es) 2025-03-11
US20180263960A1 (en) 2018-09-20
HK1245797A1 (en) 2018-08-31
CN107207431A (zh) 2017-09-26
EP3245189B1 (en) 2020-07-22
ES2825798T3 (es) 2021-05-17
CA2969814A1 (en) 2016-07-21
JP2018502083A (ja) 2018-01-25
EP3245189A2 (en) 2017-11-22
AU2016207014B2 (en) 2020-07-16
AU2016207014A1 (en) 2017-07-06
WO2016115054A2 (en) 2016-07-21
JP6764866B2 (ja) 2020-10-07
MX2017009164A (es) 2018-03-06
WO2016115054A3 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
US12110292B2 (en) Ligands to cereblon (CRBN)
CN107207431B (zh) Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途
US11542251B2 (en) IRAK degraders and uses thereof
US9284295B2 (en) Tetrahydrobenzothiophene compound
US20210038599A1 (en) Small molecule degraders of polybromo-1 (pbrm1)
CN119751465A (zh) 螺环化合物
US20140066466A1 (en) Necroptosis Inhibitors and Methods of Use Therefor
JP2010523725A (ja) 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン
RS57493B1 (sr) Novi sastavi, upotrebe i metode za njihovo spravljanje
US20170369444A1 (en) Inhibitors of histone demethylases
JP2021535134A (ja) ヘテロアリール置換スルホンアミド化合物および治療剤としてのそれらの使用
US20230192644A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
CN105085482A (zh) 取代的哌嗪化合物及其使用方法和用途
CA3181979A1 (en) Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system
KR20220132538A (ko) 디하이드로오로테이트 데하이드로게나제를 억제하는 방법 및 조성물
CA3138780C (en) Method for treating cough by using diaminopyrimidine compound
HK1245797B (en) Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof
WO2025042956A1 (en) Pde 7 modulator compounds
WO2025201531A1 (zh) 三环类化合物及其用途
US20210269418A1 (en) Hsp90 beta selective inhibitors
CA3138780A1 (en) Method for treating cough by using diaminopyrimidine compound
HK40084674A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant